CT-388
Sources
registry, as of 2026-11-05
https://clinicaltrials.gov/study/NCT07918846
A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular Disease. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Hoffmann-La Roche. Enrollment 8200. Conditions Overweight; Obesity; Cardiovascular Disease. The purpose of this study is to evaluate the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), as a therapy to reduce the risk of major adverse cardiovascular events (MACE) in adult
ClinicalTrials.gov NCT07918846 protocol and results modules
registry, as of 2026-10-13Stale
https://clinicaltrials.gov/study/NCT07351045
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes. Overall status RECRUITING. Phases PHASE3. Lead sponsor Hoffmann-La Roche. Enrollment 2000. Conditions Obesity or Overweight. The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants without Ty
ClinicalTrials.gov NCT07351045 protocol and results modules
registry, as of 2026-10-13Stale
https://clinicaltrials.gov/study/NCT07351058
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes. Overall status RECRUITING. Phases PHASE3. Lead sponsor Hoffmann-La Roche. Enrollment 1600. Conditions Obesity or Overweight; Type 2 Diabetes Mellitus. The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants with obesi
ClinicalTrials.gov NCT07351058 protocol and results modules
registry, as of 2026-11-05
https://clinicaltrials.gov/study/NCT07670416
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes. Overall status RECRUITING. Phases PHASE3. Lead sponsor Hoffmann-La Roche. Enrollment 300. Conditions Obesity; Overweight; Type 2 Diabetes Mellitus (T2DM). The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA) being developed for chronic weight management, as an adjunct to a reduced-calorie diet an
ClinicalTrials.gov NCT07670416 protocol and results modules
registry, as of 2026-11-03
https://clinicaltrials.gov/study/NCT07589686
A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight. Overall status NOT_YET_RECRUITING. Phases PHASE2. Lead sponsor Hoffmann-La Roche. Enrollment 486. Conditions Obesity or Overweight. The main purpose of this study is to evaluate the safety and efficacy of the co-administration of petrelintide and enicepatide compared with placebo, petrelintide monotherapy, and enicepatide monotherapy in participants with obesity or overweight with at least one weight-related
ClinicalTrials.gov NCT07589686 protocol and results modules
registry, as of 2026-10-05Stale
https://clinicaltrials.gov/study/NCT06525935
A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity. Overall status COMPLETED. Phases PHASE2. Lead sponsor Carmot Therapeutics, Inc.. Enrollment 469. Conditions Obesity; Overweight. This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants with obesity or who are overweight with at least one weight-related comorbidit
ClinicalTrials.gov NCT06525935 protocol and results modules
registry, as of 2026-10-28Stale
https://clinicaltrials.gov/study/NCT06628362
A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus. Overall status COMPLETED. Phases PHASE2. Lead sponsor Carmot Therapeutics, Inc.. Enrollment 447. Conditions Overweight or Obese; Type 2 Diabetes Mellitus (T2DM). This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).
ClinicalTrials.gov NCT06628362 protocol and results modules
registry, as of 2025-10-20Stale
https://clinicaltrials.gov/study/NCT04838405
A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus. Overall status COMPLETED. Phases PHASE1. Lead sponsor Carmot Therapeutics, Inc.. Enrollment 129. Conditions Diabetes. This is a first-in-human evaluation of CT-388 in a double blind, placebo controlled, randomized, SAD/MAD/MD, safety, tolerance, PK, and PD study when administered as a SC injection in otherwise healthy overweight and obese adult participants and obese participants with T2DM.
ClinicalTrials.gov NCT04838405 protocol and results modules